Tumor News and Research

RSS

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.

16 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us, an educational and authoritative website that offers free and in-depth resources for mesothelioma patients and their families, has just released a new case study that focuses on the experimental treatments for the disease.

15 Jun 2015

Study explores role of ALK1 protein in breast cancer metastasis

Pietras said that although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention.

15 Jun 2015

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).

15 Jun 2015

EORTC prospective registry targets patients with minimal sentinel node tumor burden in melanoma

Sentinel node biopsy is the standard staging procedure for melanoma patients, and sentinel node status is the most important prognostic factor for disease outcome in AJCC stage I/II disease. However, the therapeutic value of the sentinel node procedure followed by early completion lymph node dissection is still controversial.

15 Jun 2015

Ludwig Cancer Research announces opening of new branch in Lausanne, Switzerland

Ludwig Cancer Research announced today that it is opening a new Branch in Lausanne, Switzerland. The Branch will be focused primarily on applied cancer immunology and the design of novel molecular and cell-based immunotherapies. It will also develop technologies enabling the efficient, safe application of those therapies to as many patients as possible.

12 Jun 2015

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).

12 Jun 2015

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

Daily dose of aspirin effective at blocking breast tumor growth

"Take two aspirin and call me in the morning" has been the punchline for countless jokes. Could it also be good advice for cancer patients? A lab study to appear in the July 2015 issue of Laboratory Investigation found that a daily dose of aspirin was effective at blocking breast tumor growth. Previous studies have already shown a similar effect on colon, gastrointestinal, prostate, and other cancers.

12 Jun 2015

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.

12 Jun 2015

Discovery may help scientists attack the root of deadliest brain tumors

Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return. The ability of many brain tumors to regenerate can be traced to cancer stem cells that evade treatment and spur the growth of new tumor cells.

11 Jun 2015

USC Stem Cell scientist named 2015 Pew-Stewart scholar for cancer research

USC Stem Cell researcher Min Yu, MD, PhD, is one of five early-career scientists to be named a 2015 Pew-Stewart scholar for cancer research. As part of this honor, she will receive $240,000 over four years to advance the understanding of metastatic breast cancer.

11 Jun 2015

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

There is the Addams Family. And then there is the ADAMTS family. While one is mindless entertainment, the latter may prove to be a new genetic avenue for designing ovarian cancer treatment.

11 Jun 2015

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies.

11 Jun 2015

PGDx launches LungSelect product to identify genetic alterations in the plasma of NSCLC patients

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its LungSelect product that identifies the most common, clinically actionable genetic alterations in the plasma of non-small cell lung cancer (NSCLC) patients.

11 Jun 2015

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

In preliminary experiments with mice and lab-grown cells, Johns Hopkins Kimmel Cancer Center scientists have found that a protein-signaling process accelerates the work of the gene most frequently mutated in a common form of adult leukemia and is likely necessary to bring about the full-blown disease.

11 Jun 2015

Scientists find new way of classifying brain cancers

Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.

11 Jun 2015

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

A team of researchers from the Hyperbaric Biomedical Research Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer model using a novel combination of non-toxic dietary and hyperbaric oxygen therapies.

11 Jun 2015

Tumor News and Research

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Study explores role of ALK1 protein in breast cancer metastasis

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

EORTC prospective registry targets patients with minimal sentinel node tumor burden in melanoma

Ludwig Cancer Research announces opening of new branch in Lausanne, Switzerland

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Daily dose of aspirin effective at blocking breast tumor growth

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Discovery may help scientists attack the root of deadliest brain tumors

USC Stem Cell scientist named 2015 Pew-Stewart scholar for cancer research

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

PGDx launches LungSelect product to identify genetic alterations in the plasma of NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Scientists find new way of classifying brain cancers

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News